Important Differences in Gastroenterology

  • Gregory L. Hall


African Americans have the highest rate of acute hepatitis B and C virus infections of all racial groups in the US. Despite the higher occurrence of both hepatitis B and C, African Americans tend to be screened less often, and once diagnosed are referred for specialty care less often. The availability of DAA-based therapies for HCV cure has significantly improved treatment eligibility, treatment initiation, and treatment successes in African American patients. African Americans have increased risk for hepatocellular carcinoma and the related mortality, and it occurs at a significantly earlier age. GERD has a similar occurrence in African Americans when compared to European Americans but has a much lower transformation to esophagitis or adenocarcinoma. Barrett’s esophagus also has a decreased prevalence in African Americans. Finally, there is a higher prevalence of Helicobacter pylori infections in African Americans.


  1. 1.
    Forde KA, Tanapanpanit O, Reddy KR. Hepatitis B and C in African Americans: current status and continued challenges. Clin Gastroenterol Hepatol. 2014;12(5):738–48.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Wasley A, Kruszon-Moran D, Kuhnert W, Simard EP, Finelli L, McQuillan G, et al. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis. 2010;202(2):192–201.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Carroll KC, Hobden JA, Miller S, Morse SA, Mietzner TA, Detrick B, Mitchell TG, McKerrow JH, Sakanari JA, editors. Hepatitis viruses. In: Jawetz, Melnick, & Adelberg’s medical microbiology. New York: McGraw-Hill. p. 27e; Accessed 12 May 2019.
  4. 4.
    Hepatitis B Questions and Answers for the Public. Centers for Disease Control and Prevention. Accessed 12 May 2019.
  5. 5.
    Forde F. Ethnic disparities in chronic hepatitis B infection: African American and Hispanic Americans. Curr Hepatol Rep. 2017;16(2):105–12.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Hennessey KA, Kim AA, Griffin V, et al. Prevalence of infection with hepatitis B and C viruses and co-infection with HIV in three jails: a case for viral hepatitis prevention in jails in the United States. J Urban Health. 2009;86(1):93–105.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Statistics Inmate Race. Federal Bureau of Prisons. 2019. Accessed 12 May 2019.
  8. 8.
    Gupta S, Altice FL. Hepatitis B virus infection in US correctional facilities: a review of diagnosis, management, and public health implications. J Urban Health. 2009;86(2):263–79.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Hu DJ, Xing J, Tohme RA, Liao Y, Pollack H, Ward JW, et al. Hepatitis B testing and access to care among racial and ethnic minorities in selected communities across the United States, 2009–2010. Hepatology. 2013;58(3):856–62.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Sorrell MF, Belongia EA, Costa J, et al. National institutes of health consensus development conference of hepatitis B. Ann Intern Med. 2009;150(2):104–10.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Sunbul M. Hepatitis B virus genotypes: global distribution and clinical importance. World J Gastroenterol. 2014;20(18):5427–34.PubMedPubMedCentralGoogle Scholar
  12. 12.
    DiBisceglie AM, King WC, Lisker-Melman M, et al. Age, race and viral genotype are associated with the prevalence of hepatitis B antigen in children and adults with chronic hepatitis. J Viral Hepat. 2019. Assessed 12 May 2019.
  13. 13.
    Denniston MM, Jiles RB, Drobeniuc J, et al. Hepatitis C virus infection in the United States, national health and nutrition examination survey 2003 to 2010. Ann Intern Med. 2014;160(5):293–300.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Wilder J, Saraswathula A, Hasselblad V, Muir A. A systematic review of race and ethnicity in hepatitis C clinical trial enrollment. J Natl Med Assoc. 2016;108(1):24–9.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology. 2006;131(2):470–7.Google Scholar
  16. 16.
    Saab S, Jackson C, Nieto J, Francois F. Hepatitis C in African Americans. Am J Gastroenterol. 2014;109(10):1576–84.Google Scholar
  17. 17.
    Talal AH, LaFleur J, Hoop R, et al. Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV-infected, evaluated patients. Aliment Pharmacol Ther. 2013;37(4):473–81.Google Scholar
  18. 18.
    Rowan PJ, Tabasi S, Abdul-Latif M, et al. Psychosocial factors are the most common contraindications for antiviral therapy at initial evaluation in veterans with chronic hepatitis C. J Clin Gastroenterol. 2004;38:530–4.Google Scholar
  19. 19.
    Teshale EH, Xing J, Moorman A, et al. Higher all-cause hospitalization among patients with chronic hepatitis C: the Chronic Hepatitis C Cohort Study (CHeCS), 2006–2013. J Viral Hepat. 2016;23(10):748–54.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Trooskin SB, Navarro VJ, Winn RJ, et al. Hepatitis C risk assessment, testing and referral for treatment in urban primary care: role of race ethnicity. World J Gastroenterol. 2007;13(7):1074–8.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Khokhar OS, Lewis JH. Reasons why patients infected with chronic hepatitis C virus choose to defer treatment: do they alter their decision with time? Dig Dis Sci. 2007;52(5):1168–76.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Borum ML, Igiehon E, Shafa S, et al. African Americans may differ in their reasons for declining hepatitis C therapy compared to non-African Americans. Dig Dis Sci. 2009;54:1604–5.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis c virus infection: host, viral, and environmental factors. JAMA. 2000;284:450–6.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Mir HM, Stepanova M, Afendy M, et al. African Americans are less likely to have clearance of hepatitis C virus infection: the findings from recent U.S. population data. J Clin Gastroenterol. 2012;46(8):e62–5.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Sterling RK, Stravitz RT, Luketic VA, et al. A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans. Clin Gastroenterol Hepatol. 2004;2(6):469–73.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Crosse K, Umeadi OG, Anania FA, et al. Racial difference in liver inflammation and fibrosis related to chronic hepatitis C. Clin Gastroenterol Hepatol. 2004;2(6):463–8.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Marcus JL, Hurley LB, Chamberland S. Disparities in initiation of direct-acting antiviral agents for hepatitis C virus infection in an insured population. Public Health Rep. 2018;133(4):452–60.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Sims OT, Guo Y, Shoreibah MG, et al. Short article: alcohol and substance use, race, and insurance status predict nontreatment for hepatitis C virus in the era of direct acting antivirals: a retrospective study in a large urban tertiary center. Eur J Gastroenterol Hepatol. 2017;29(11):12191222.Google Scholar
  29. 29.
    Beck KR, Kim NJ, Khalili M. Direct acting antivirals improve HCV treatment initiation and adherence among underserved African Americans. Ann Hepatol. 2018;17(3):413–8.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Kim AK, Singal AG. Health disparities in diagnosis and treatment of hepatocellular carcinoma. Clin Liver Dis (Hoboken). 2015;4(6):143–5.Google Scholar
  31. 31.
    Yu L, Sloane DA, Guo C, Howell CD. Risk factors for primary hepatocellular carcinoma in black and white Americans in 2000. Clin Gastroenterol Hepatol. 2006;4(3):355–60.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Davila JA, Morgan RO, Richardson PA, et al. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology. 2010;52:132–41.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Zak Y, Rhoads KF, Visser BC. Predictors of surgical intervention for hepatocellular carcinoma: race, socioeconomic status, and hospital type. Arch Surg. 2011;146(7):778–84.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Aniwan S, Harmsen WS, Tremaine WJ, et al. Incidence of inflammatory bowel disease by race and ethnicity in a population-based inception cohort from 1970 through 2010. Ther Adv Gastroenterol. 2019;12:1756284819827692.Google Scholar
  35. 35.
    McQuaid KR. Gastrointestinal disorders. In: Papadakis MA, McPhee SJ, Rabow MW, editors. Current medical diagnosis & treatment. New York: McGraw-Hill; 2019; Accessed 05 June 2019.Google Scholar
  36. 36.
    Nguyen GC, Torres EA, Regueiro M, et al. Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. Am J Gastroenterol. 2006;101(5):1012–23.Google Scholar
  37. 37.
    Bertha M, Vasantharoopan A, Kumar A, et al. IBD Serology and disease outcomes in African Americans with Crohn’s disease. Inflamm Bowel Dis. 2018;24(1):209–16.Google Scholar
  38. 38.
    Sofia MA, Rubin DT, Hou N, Pekow J. Clinical presentation and disease course of inflammatory bowel disease differs by race in a large tertiary care hospital. Dig Dis Sci. 2014;59(9):2228–35.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Nguyen GC, LaVeist TA, Harris ML, et al. Racial disparities in utilization of specialist care and medications in inflammatory bowel disease. Am J Gastroenterol. 2010;105(10):2202–8.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Arsoniadis EG, Ho YY, Melton GB, Madoff RD, et al. African Americans and short-term outcomes after surgery for Crohn’s disease: an ACS-NSQIP analysis. J Crohns Colitis. 2017;11(4):468–73.PubMedPubMedCentralGoogle Scholar
  41. 41.
    El-Serag HB, Petersen NJ, Carter J, et al. Gastroesophageal reflux among different racial groups in the United States. Gastroenterology. 2004;126(7):1692–9.PubMedPubMedCentralGoogle Scholar
  42. 42.
    Spechler SJ, Jain SK, Tendler DA, Parker RA. Racial differences in the frequency of symptoms and complications of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2002;16(10):1795–800.PubMedPubMedCentralGoogle Scholar
  43. 43.
    Alkaddour A, McGaw C, Hritani R, et al. Protective propensity of race or environmental features in the development of Barrett’s esophagus in African Americans – a single center pilot study. J Natl Med Assoc. 2019;111(2):198–201.PubMedPubMedCentralGoogle Scholar
  44. 44.
    Alkaddour A, McGaw C, Hritani R, et al. African American ethnicity is not associated with development of Barrett’s esophagus after erosive esophagitis. Dig Liver Dis. 2015;47(10):853–6.PubMedPubMedCentralGoogle Scholar
  45. 45.
    Grad Y, Lipsitch M, Aiello AE. Secular trends in Helicobacter pylori seroprevalence in adults in the United States: evidence for sustained race/ethnic disparities. Am J Epidemiol. 2012;175(1):54–9.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Parsonnet J. The incidence of Helicobacter pylori infection. Aliment Pharmacol Ther. 1995;9(suppl 2):45–51.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Nguyen T, Ramsey D, Graham D, et al. The prevalence of Helicobacter pylori remains high in African Americans and Hispanic veterans. Helicobacter. 2015;20(4):305–15.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Stinton LM, Shaffer EA. Epidemiology of gallbladder disease: cholelithiasis and cancer. Gut Liver. 2012;6(2):172–87.PubMedPubMedCentralGoogle Scholar
  49. 49.
    Figueiredo JC, Haiman C, Porcel J, et al. Sex and ethnic/racial-specific risk factors for gallbladder disease. BMC Gastroenterol. 2017;17(1):153.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Gregory L. Hall
    • 1
  1. 1.Partnerships for Urban HealthCleveland State UniversityClevelandUSA

Personalised recommendations